Loading…
DNMT3A promotes glioma growth and malignancy via TNF-α/NF-κB signaling pathway
DNMT3A is the main molecule responsible for DNA methylation in cells. DNMT3A affects the progression of inflammation, degenerative diseases, and malignant tumors, and exhibits significant aberrantly expression in tumor tissues. Transcriptome data and relevant clinical information were downloaded fro...
Saved in:
| Published in: | Translational cancer research 2024-04, Vol.13 (4), p.1786-1806 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 1806 |
| container_issue | 4 |
| container_start_page | 1786 |
| container_title | Translational cancer research |
| container_volume | 13 |
| creator | Su, Xiaoyan Liu, Junzhe Tu, Zewei Ji, Qiankun Li, Jingying Liu, Fanrong |
| description | DNMT3A is the main molecule responsible for DNA methylation in cells. DNMT3A affects the progression of inflammation, degenerative diseases, and malignant tumors, and exhibits significant aberrantly expression in tumor tissues.
Transcriptome data and relevant clinical information were downloaded from The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), and Gene Expression Omnibus (GEO) datasets. Differential expression analysis and prognostic analysis were conducted based on above statistics. We constructed a clinical prognostic model and identified
as an independent prognostic factor to accurately predict patient prognosis. Differential gene enrichment analysis revealed that DNMT3A affects the progression of glioma through multiple pathways, among which the tumor necrosis factor-α (TNF-α)/nuclear factor-kappa B (NF-κB) pathway shows a strong correlation. Immunological analysis also revealed a certain correlation between DNMT3A and tumor immunity. We demonstrated through gene editing that DNMT3A can affect the release of TNF-α in cells, thereby affecting the progression of glioma. Functional experiments have also demonstrated that DNMT3A plays a crucial role in tumors.
RNA-sequencing and survival analyses of lower-grade glioma (LGG) patients in TCGA, CGGA, and GEO cohorts showed that high
expression correlated with poor prognosis of LGG patients. Univariate and multivariate Cox regression analyses showed that
expression was an independent prognostic indicator in LGG. The prognosis prediction nomogram with age, World Health Organization (WHO) grading, and
expression showed reliable performance in predicting the 1-, 3-, and 5-year overall survival (OS) of LGG patients. Functional enrichment analysis, gene set enrichment analysis (GSEA), and ESTIMATE algorithm analyses showed that DNMT3A expression was associated with the tumor infiltration of immune cells and predicted response to immunotherapy in two immunotherapy cohorts of pan-cancer patients. Furthermore, short hairpin RNA (shRNA)-mediated knockdown of DNMT3A in the LGG cell lines suppressed proliferation, migration, and invasion of LGG cells by downregulating the TNF-α/NF-κB signaling pathway.
Our data showed that DNMT3A was a potential prognostic biomarker in glioma. DNMT3A promoted proliferation and malignancy of LGG cells through the TNF-α/NF-κB signaling pathway. DNMT3A is a promising therapeutic target for treating patients with LGG. |
| doi_str_mv | 10.21037/tcr-23-1943 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3054431201</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3054431201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c286t-22d12e80040b699349a8e2319bb8eeae953a4a8ddd431fd6920e6e6ca756399e3</originalsourceid><addsrcrecordid>eNo9kE1PAjEQhhujEYLcPJsePVhpO0u3PSKKmiB6wMRb090dYM1-4HaR8LO8-iP8TS4fepmZZJ55M3kIORf8WgoOYa-OKyaBCRPAEWlLKQxTmsPxbtZMheqtRbrev3POpRA64OqUtECHECoDbfJyO3mawoAuqzIva_R0nqVl7ui8Ktf1groiobnL0nnhinhDP1NHp5MR-_nqbev3DfXbVZYWc7p09WLtNmfkZOYyj91D75DX0d10-MDGz_ePw8GYxVKrmkmZCIma84BHyhgIjNMoQZgo0ogOTR9c4HSSJAGIWaKM5KhQxS7sKzAGoUMu97nN5x8r9LXNUx9jlrkCy5W3wPtBcyq5aNCrPRpXpfcVzuyySnNXbazgdqfRNhqtBLvV2OAXh-RVlGPyD_9Jg18hMG2D</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3054431201</pqid></control><display><type>article</type><title>DNMT3A promotes glioma growth and malignancy via TNF-α/NF-κB signaling pathway</title><source>Open Access: PubMed Central</source><creator>Su, Xiaoyan ; Liu, Junzhe ; Tu, Zewei ; Ji, Qiankun ; Li, Jingying ; Liu, Fanrong</creator><creatorcontrib>Su, Xiaoyan ; Liu, Junzhe ; Tu, Zewei ; Ji, Qiankun ; Li, Jingying ; Liu, Fanrong</creatorcontrib><description>DNMT3A is the main molecule responsible for DNA methylation in cells. DNMT3A affects the progression of inflammation, degenerative diseases, and malignant tumors, and exhibits significant aberrantly expression in tumor tissues.
Transcriptome data and relevant clinical information were downloaded from The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), and Gene Expression Omnibus (GEO) datasets. Differential expression analysis and prognostic analysis were conducted based on above statistics. We constructed a clinical prognostic model and identified
as an independent prognostic factor to accurately predict patient prognosis. Differential gene enrichment analysis revealed that DNMT3A affects the progression of glioma through multiple pathways, among which the tumor necrosis factor-α (TNF-α)/nuclear factor-kappa B (NF-κB) pathway shows a strong correlation. Immunological analysis also revealed a certain correlation between DNMT3A and tumor immunity. We demonstrated through gene editing that DNMT3A can affect the release of TNF-α in cells, thereby affecting the progression of glioma. Functional experiments have also demonstrated that DNMT3A plays a crucial role in tumors.
RNA-sequencing and survival analyses of lower-grade glioma (LGG) patients in TCGA, CGGA, and GEO cohorts showed that high
expression correlated with poor prognosis of LGG patients. Univariate and multivariate Cox regression analyses showed that
expression was an independent prognostic indicator in LGG. The prognosis prediction nomogram with age, World Health Organization (WHO) grading, and
expression showed reliable performance in predicting the 1-, 3-, and 5-year overall survival (OS) of LGG patients. Functional enrichment analysis, gene set enrichment analysis (GSEA), and ESTIMATE algorithm analyses showed that DNMT3A expression was associated with the tumor infiltration of immune cells and predicted response to immunotherapy in two immunotherapy cohorts of pan-cancer patients. Furthermore, short hairpin RNA (shRNA)-mediated knockdown of DNMT3A in the LGG cell lines suppressed proliferation, migration, and invasion of LGG cells by downregulating the TNF-α/NF-κB signaling pathway.
Our data showed that DNMT3A was a potential prognostic biomarker in glioma. DNMT3A promoted proliferation and malignancy of LGG cells through the TNF-α/NF-κB signaling pathway. DNMT3A is a promising therapeutic target for treating patients with LGG.</description><identifier>ISSN: 2218-676X</identifier><identifier>EISSN: 2219-6803</identifier><identifier>DOI: 10.21037/tcr-23-1943</identifier><identifier>PMID: 38737693</identifier><language>eng</language><publisher>China</publisher><ispartof>Translational cancer research, 2024-04, Vol.13 (4), p.1786-1806</ispartof><rights>2024 Translational Cancer Research. All rights reserved.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38737693$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Su, Xiaoyan</creatorcontrib><creatorcontrib>Liu, Junzhe</creatorcontrib><creatorcontrib>Tu, Zewei</creatorcontrib><creatorcontrib>Ji, Qiankun</creatorcontrib><creatorcontrib>Li, Jingying</creatorcontrib><creatorcontrib>Liu, Fanrong</creatorcontrib><title>DNMT3A promotes glioma growth and malignancy via TNF-α/NF-κB signaling pathway</title><title>Translational cancer research</title><addtitle>Transl Cancer Res</addtitle><description>DNMT3A is the main molecule responsible for DNA methylation in cells. DNMT3A affects the progression of inflammation, degenerative diseases, and malignant tumors, and exhibits significant aberrantly expression in tumor tissues.
Transcriptome data and relevant clinical information were downloaded from The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), and Gene Expression Omnibus (GEO) datasets. Differential expression analysis and prognostic analysis were conducted based on above statistics. We constructed a clinical prognostic model and identified
as an independent prognostic factor to accurately predict patient prognosis. Differential gene enrichment analysis revealed that DNMT3A affects the progression of glioma through multiple pathways, among which the tumor necrosis factor-α (TNF-α)/nuclear factor-kappa B (NF-κB) pathway shows a strong correlation. Immunological analysis also revealed a certain correlation between DNMT3A and tumor immunity. We demonstrated through gene editing that DNMT3A can affect the release of TNF-α in cells, thereby affecting the progression of glioma. Functional experiments have also demonstrated that DNMT3A plays a crucial role in tumors.
RNA-sequencing and survival analyses of lower-grade glioma (LGG) patients in TCGA, CGGA, and GEO cohorts showed that high
expression correlated with poor prognosis of LGG patients. Univariate and multivariate Cox regression analyses showed that
expression was an independent prognostic indicator in LGG. The prognosis prediction nomogram with age, World Health Organization (WHO) grading, and
expression showed reliable performance in predicting the 1-, 3-, and 5-year overall survival (OS) of LGG patients. Functional enrichment analysis, gene set enrichment analysis (GSEA), and ESTIMATE algorithm analyses showed that DNMT3A expression was associated with the tumor infiltration of immune cells and predicted response to immunotherapy in two immunotherapy cohorts of pan-cancer patients. Furthermore, short hairpin RNA (shRNA)-mediated knockdown of DNMT3A in the LGG cell lines suppressed proliferation, migration, and invasion of LGG cells by downregulating the TNF-α/NF-κB signaling pathway.
Our data showed that DNMT3A was a potential prognostic biomarker in glioma. DNMT3A promoted proliferation and malignancy of LGG cells through the TNF-α/NF-κB signaling pathway. DNMT3A is a promising therapeutic target for treating patients with LGG.</description><issn>2218-676X</issn><issn>2219-6803</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kE1PAjEQhhujEYLcPJsePVhpO0u3PSKKmiB6wMRb090dYM1-4HaR8LO8-iP8TS4fepmZZJ55M3kIORf8WgoOYa-OKyaBCRPAEWlLKQxTmsPxbtZMheqtRbrev3POpRA64OqUtECHECoDbfJyO3mawoAuqzIva_R0nqVl7ui8Ktf1groiobnL0nnhinhDP1NHp5MR-_nqbev3DfXbVZYWc7p09WLtNmfkZOYyj91D75DX0d10-MDGz_ePw8GYxVKrmkmZCIma84BHyhgIjNMoQZgo0ogOTR9c4HSSJAGIWaKM5KhQxS7sKzAGoUMu97nN5x8r9LXNUx9jlrkCy5W3wPtBcyq5aNCrPRpXpfcVzuyySnNXbazgdqfRNhqtBLvV2OAXh-RVlGPyD_9Jg18hMG2D</recordid><startdate>20240430</startdate><enddate>20240430</enddate><creator>Su, Xiaoyan</creator><creator>Liu, Junzhe</creator><creator>Tu, Zewei</creator><creator>Ji, Qiankun</creator><creator>Li, Jingying</creator><creator>Liu, Fanrong</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240430</creationdate><title>DNMT3A promotes glioma growth and malignancy via TNF-α/NF-κB signaling pathway</title><author>Su, Xiaoyan ; Liu, Junzhe ; Tu, Zewei ; Ji, Qiankun ; Li, Jingying ; Liu, Fanrong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c286t-22d12e80040b699349a8e2319bb8eeae953a4a8ddd431fd6920e6e6ca756399e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Su, Xiaoyan</creatorcontrib><creatorcontrib>Liu, Junzhe</creatorcontrib><creatorcontrib>Tu, Zewei</creatorcontrib><creatorcontrib>Ji, Qiankun</creatorcontrib><creatorcontrib>Li, Jingying</creatorcontrib><creatorcontrib>Liu, Fanrong</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Translational cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Su, Xiaoyan</au><au>Liu, Junzhe</au><au>Tu, Zewei</au><au>Ji, Qiankun</au><au>Li, Jingying</au><au>Liu, Fanrong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>DNMT3A promotes glioma growth and malignancy via TNF-α/NF-κB signaling pathway</atitle><jtitle>Translational cancer research</jtitle><addtitle>Transl Cancer Res</addtitle><date>2024-04-30</date><risdate>2024</risdate><volume>13</volume><issue>4</issue><spage>1786</spage><epage>1806</epage><pages>1786-1806</pages><issn>2218-676X</issn><eissn>2219-6803</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>DNMT3A is the main molecule responsible for DNA methylation in cells. DNMT3A affects the progression of inflammation, degenerative diseases, and malignant tumors, and exhibits significant aberrantly expression in tumor tissues.
Transcriptome data and relevant clinical information were downloaded from The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), and Gene Expression Omnibus (GEO) datasets. Differential expression analysis and prognostic analysis were conducted based on above statistics. We constructed a clinical prognostic model and identified
as an independent prognostic factor to accurately predict patient prognosis. Differential gene enrichment analysis revealed that DNMT3A affects the progression of glioma through multiple pathways, among which the tumor necrosis factor-α (TNF-α)/nuclear factor-kappa B (NF-κB) pathway shows a strong correlation. Immunological analysis also revealed a certain correlation between DNMT3A and tumor immunity. We demonstrated through gene editing that DNMT3A can affect the release of TNF-α in cells, thereby affecting the progression of glioma. Functional experiments have also demonstrated that DNMT3A plays a crucial role in tumors.
RNA-sequencing and survival analyses of lower-grade glioma (LGG) patients in TCGA, CGGA, and GEO cohorts showed that high
expression correlated with poor prognosis of LGG patients. Univariate and multivariate Cox regression analyses showed that
expression was an independent prognostic indicator in LGG. The prognosis prediction nomogram with age, World Health Organization (WHO) grading, and
expression showed reliable performance in predicting the 1-, 3-, and 5-year overall survival (OS) of LGG patients. Functional enrichment analysis, gene set enrichment analysis (GSEA), and ESTIMATE algorithm analyses showed that DNMT3A expression was associated with the tumor infiltration of immune cells and predicted response to immunotherapy in two immunotherapy cohorts of pan-cancer patients. Furthermore, short hairpin RNA (shRNA)-mediated knockdown of DNMT3A in the LGG cell lines suppressed proliferation, migration, and invasion of LGG cells by downregulating the TNF-α/NF-κB signaling pathway.
Our data showed that DNMT3A was a potential prognostic biomarker in glioma. DNMT3A promoted proliferation and malignancy of LGG cells through the TNF-α/NF-κB signaling pathway. DNMT3A is a promising therapeutic target for treating patients with LGG.</abstract><cop>China</cop><pmid>38737693</pmid><doi>10.21037/tcr-23-1943</doi><tpages>21</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2218-676X |
| ispartof | Translational cancer research, 2024-04, Vol.13 (4), p.1786-1806 |
| issn | 2218-676X 2219-6803 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3054431201 |
| source | Open Access: PubMed Central |
| title | DNMT3A promotes glioma growth and malignancy via TNF-α/NF-κB signaling pathway |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T03%3A33%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=DNMT3A%20promotes%20glioma%20growth%20and%20malignancy%20via%20TNF-%CE%B1/NF-%CE%BAB%20signaling%20pathway&rft.jtitle=Translational%20cancer%20research&rft.au=Su,%20Xiaoyan&rft.date=2024-04-30&rft.volume=13&rft.issue=4&rft.spage=1786&rft.epage=1806&rft.pages=1786-1806&rft.issn=2218-676X&rft.eissn=2219-6803&rft_id=info:doi/10.21037/tcr-23-1943&rft_dat=%3Cproquest_cross%3E3054431201%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c286t-22d12e80040b699349a8e2319bb8eeae953a4a8ddd431fd6920e6e6ca756399e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3054431201&rft_id=info:pmid/38737693&rfr_iscdi=true |